JACC:慢性心力衰竭患者肠血流量减少

2014-09-28 伊文 国际循环

最近一项前瞻性研究结果显示,慢性心力衰竭(心衰)患者较无心衰患者肠血流量减少。这可能导致细菌生长增加和胃肠道症状。 研究者共纳入65例慢性心衰患者和25例对照者。结果显示慢性心衰患者肠动脉血流减少,可导致近粘膜处细菌生长、炎症、胃肠道症状及心衰晚期并发的心源性恶病质。心衰的严重程度与肠系膜上动脉和腹腔动脉的血流减少显著相关(P<0.04)。慢性心衰患者肠系膜上下动脉、腹腔动脉收缩期血流较对

最近一项前瞻性研究结果显示,慢性心力衰竭心衰)患者较无心衰患者肠血流量减少。这可能导致细菌生长增加和胃肠道症状。

研究者共纳入65例慢性心衰患者和25例对照者。结果显示慢性心衰患者肠动脉血流减少,可导致近粘膜处细菌生长、炎症、胃肠道症状及心衰晚期并发的心源性恶病质。心衰的严重程度与肠系膜上动脉和腹腔动脉的血流减少显著相关(P<0.04)。慢性心衰患者肠系膜上下动脉、腹腔动脉收缩期血流较对照组下降30%~43%(P<0.007)。发生恶病质的患者血流量减少更明显(P<0.002)。

心衰组小肠、升结肠、降结肠、乙状结肠、横结肠肠壁厚度较对照组增厚(P<0.01),胃肠道症状也更频繁,包括上腹部饱胀感、呃逆和肠道杂音(P分别为0.014、0.016、0.027)。其中呃逆、肠道杂音在恶病质患者中症状更重。

低血流量显著增加腹部不适症状,血清抗脂多糖IgA(r=0.76,P<0.02)和CRP(r=0.43,P=0.02)明显升高。慢性心衰患者近粘膜细菌生长率高,且与低血流量和血清抗脂多糖IgA明显相关(r=0.55,P=0.05)。

多变量分析显示,心源性恶病质与肠系膜上动脉低血流量明显相关(P<0.04),与肠系膜下动脉低血流量临界于有显著性意义的边缘(P=0.056)。

英国赫尔约克医学院城堡山医院Benjamin Dicken和伦敦帝国理工学院John G.F. Cleland博士均对上述结果持怀疑态度。他们认为,许多心血管药物,如利尿剂、盐皮质激素阻断剂均对肠道功能有影响,另外对照组的活体组织检查也未能真实的反映健康人群。

Dicken和Cleland认同通过抗生素或改变肠道内环境的方式改变细菌的数量或种类,进而评估肠道细菌和心衰进程的关联研究。但任何一种方法要证明有效,均需要大规模研究来评估

原始出处

Dicken B1, Cleland JG2.Is the Way to a Man's Heart Through His Stomach?: Intestinal Blood Flow, Gut Permeability, and Heart Failure.J Am Coll Cardiol. 2014 Sep 16

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2075886, encodeId=ad0820e5886e9, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Dec 13 03:18:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853294, encodeId=4404185329423, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 28 16:18:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251769, encodeId=e37f1251e693e, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324959, encodeId=39dc13249599b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2075886, encodeId=ad0820e5886e9, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Dec 13 03:18:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853294, encodeId=4404185329423, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 28 16:18:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251769, encodeId=e37f1251e693e, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324959, encodeId=39dc13249599b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
    2015-04-28 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=2075886, encodeId=ad0820e5886e9, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Dec 13 03:18:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853294, encodeId=4404185329423, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 28 16:18:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251769, encodeId=e37f1251e693e, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324959, encodeId=39dc13249599b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2075886, encodeId=ad0820e5886e9, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sat Dec 13 03:18:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853294, encodeId=4404185329423, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Tue Apr 28 16:18:00 CST 2015, time=2015-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1251769, encodeId=e37f1251e693e, content=<a href='/topic/show?id=ac5d5351ea8' target=_blank style='color:#2F92EE;'>#慢性心力衰竭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53517, encryptionId=ac5d5351ea8, topicName=慢性心力衰竭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324959, encodeId=39dc13249599b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Tue Sep 30 00:18:00 CST 2014, time=2014-09-30, status=1, ipAttribution=)]

相关资讯

Circulation:睡眠呼吸障碍增加慢性心衰患者致死性室性心律失常的发生

慢性心力衰竭(Chronic heart failure,CHF)在临床上十分常见,近年来随着药物及器械治疗的飞速进展,CHF的预后得到了很大的改善,但是CHF仍然有很高的死亡率和心脏性猝死的发生率。为改善CHF的预后,我们需要积极寻找增加患者死亡率和心脏性猝死发生率的因素。近年来的研究表明,约50%的慢性心力衰竭患者合并睡眠呼吸障碍,包括阻塞性睡眠呼吸障碍和中枢性睡眠呼吸障碍,多项大规模临床研究

郭艺芳:β受体阻滞剂不会走下神坛

长期以来,β受体阻滞剂(BB)在多种心血管疾病的治疗中一直发挥着关键作用。从冠心病到慢性心力衰竭,从高血压到心律失常,此类药物的临床应用非常广泛,在心血管病药物治疗领域享有独特地位。然而,近来一些新的研究结果不断质疑、挑战、冲击着BB的传统地位,甚至有些学者认为此类药物正在走下神坛。 1.近期关于BB的部分学术动态 降压领域 多年以来BB一直作为治疗高血压的重要药物之一。但随

心脏再同步治疗慢性心力衰竭进展

近日,在2013中国心脏大会上,阜外心血管病医院华伟教授作了题为《心脏再同步治疗慢性心力衰竭进展》的报告。心衰的诊断血浆N末端B型钠尿肽(NT-proBNP)是良好的排除试验指标:急诊科设定:判断限=300ng/L(NPV>98%),作为排除心衰的依据。如果要诊断心衰,则要根据不同的年龄运用不同的阈值进行判断。心衰预后与疗效监测NT-proBNP是短期——长期心脏病问题的强烈指标。住院期间NT-p